-
Product Insights
Ischemia Reperfusion Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-248 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Solid Tumor Drug Details: AB-248 is under development for the treatment of locally...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MZE-001 in Pompe Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MZE-001 in Pompe Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MZE-001 in Pompe Disease Drug Details:MZE-001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aminolevulinic Acid Hydrochloride in Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Aminolevulinic Acid Hydrochloride in Anemia Drug Details:Aminolevulinic acid hydrochloride (5-ALA) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aminolevulinic Acid Hydrochloride in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Aminolevulinic Acid Hydrochloride in Mild Cognitive ImpairmentDrug Details:Aminolevulinic acid hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-7789 in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-7789 in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-7789 in Non-Small Cell Lung Carcinoma Drug Details: AZD-7789 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YT-1920 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YT-1920 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR)...